Amneal Pharmaceuticals, Inc. (AMRX) - Stock Analysis
Last updated: Jun 14, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Positive catalyst stack with FDA approval of romidepsin injection solution including 180 days of exclusivity, solid Q1 2026 revenue/adjusted EBITDA, reaffirmed higher full-year guidance, and a 14% 21-day stock uptrend with recent breakout strength.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin expansion ⢠Negative equity ⢠Cash burn AMRX shows improving margins and interest coverage, but heavy debt, negative equity, and Q1 cash burn keep it a high-risk turnaround dependent on sustained earnings quality.
Price Behavior
Key Price Behavior Insights: ⢠Higher-low trend ⢠Breakout support ⢠Stretched rally Support Level: $14.70â$15.30 Resistance Level: $16.34 The stock has shifted into a bullish higher-high/higher-low trend since 11.81, broke above 13.70â13.90, and now has 14.70â15.30 as near-term support, though the rapid run leaves it stretched into 16.34 resistance.
Sentiment & News
Key News Insights: ⢠Biosimilar Growth ⢠FDA Approval ⢠Valuation Risk AMRX was presented as a growth-focused momentum story, driven by specialty drugs, biosimilars, FDA approval and CREXONT progress, though the recent rally also raised overvaluation concerns.
AI Summary
AMRX's investable thesis is shifting from a low-value generic maker to a higher-value specialty/biologics story, but the stock only works if management turns improving margins and new launches into sustained free cash flowâotherwise the heavy leverage and negative equity make the current rally vulnerable.
Description
Amneal Pharmaceuticals is a manufacturer and distributor of generic and specialty medicines, operating three reporting segments: Generics, Specialty and AvKARE. Its Generics business produces a broad range of dosage forms while the Specialty unit markets branded therapies across several therapeutic areas; AvKARE supplies pharmaceuticals, medical and surgical products, and packaging services primarily to government and institutional customers. The company sells through wholesalers, hospitals and pharmacies, and maintains operations in the United States, India, Ireland and other international markets; it is headquartered in Bridgewater, New Jersey and was founded in 2002.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 9 | Jun 16 | AMRX | Amneal Pharmaceuticals, Inc. | Positive catalyst stack with FDA approval of romidepsin injection solution including 180 days of exclusivity, solid Q1 2026 revenue/adjusted EBITDA, reaffirmed higher full-year guidance, and a 14% 21-day stock uptrend with recent breakout strength. | Closed | +10.6% |